A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)

This study looks at how the body processes a cancer drug called loncastuximab tesirine in patients with a type of aggressive blood cancer (diffuse large B-cell lymphoma or high-grade B-cell lymphoma) who also have liver problems. Researchers want to understand if liver impairment changes how the drug works and whether dose adjustments are needed. **You may be eligible if...** - You are 18 or older - You have been diagnosed with relapsed or treatment-resistant diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma - You have had at least one prior treatment for your lymphoma - You have either normal liver function, moderate liver impairment, or severe liver impairment (the study has different arms for each) - You have measurable disease - You are in reasonably good health overall (ECOG 0–3 depending on liver status) **You may NOT be eligible if...** - You have not previously received any treatment for your lymphoma - Your disease does not meet the study's definition of relapsed or refractory - You are pregnant or breastfeeding, or unwilling to use contraception during and for months after the study - You have conditions that prevent safe participation Talk to your doctor to see if this trial is right for you.